Understanding the role of NLRP3 inflammasome activation in gout flares points to potential of NLRP3 inflammasome inhibitors as new treatment option.
Search results for: Gout
SAP-001 Promising for Refractory Gout
Initial findings from a phase 2b clinical trial demonstrate the safety and efficacy of three different daily doses of SAP-001 to lower the serum urate levels of patients with refractory gout.
FDA Approves Oral Solution of Colchicine to Prevent Gout Flare
The FDA approved an oral solution of colchicine for the prevention of gout flare in adults. Its dosage can be easily adjusted on the basis of patient needs.
Top Research in Gout from ACR Convergence 2024 at a Glance
Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2024.
Better Education on Gout
Experts addressed how education and follow-up for patients with gout can improve disease management and highlighted the need for a better construction of gout remission.
Lubricin/CD44/PP2A Pathway Offers New Therapeutic Targets for Patients with Gout
Dr. Khaled Elsaid discussed synovial macrophages/monocytes and monosodium urate crystal interactions at a session during ACR Convergence, exploring potential new gout pharmacology targets via the lubricin/CD44/protein phosphatase 2A (PP2A) pathway.
Progress in Gout Education & Remission
An ACR Convergence 2024 session will discuss strategies to educate patients about their disease and review the progress toward the concept of remission in gout to better guide physicians.
Novel Mechanisms of Gout Explored
In a session at ACR Convergence 2024, expert panelists with go into depth concerning molecular mechanisms that contribute to gout pathogenesis.
Your Gout Guide for ACR Convergence 2024: Dr. Lisa Stamp
Lisa Stamp, MBChB, PhD, is here to help the busy clinician by curating a collection of the most significant and notable abstracts in gout research to be presented at ACR Convergence 2024.
3 AC&R Study Summaries: Frailty & Prefrailty in RA, Premature Mortality in Gout & Using Recruitment & Multidisciplinary Care Incentives to Improve Access
Frailty & Prefrailty in Patients with RA TNF-α inhibitors associated with higher infection risk By Namrata Singh, MD, MSCI, Katherine D. Wysham, MD, James S. Andrews, MD, & Una E. Makris, MD Why was this study done? Frailty and prefrailty are more common and occur at a younger age in patients with rheumatoid arthritis (RA)…
- 1
- 2
- 3
- …
- 59
- Next Page »